JP2007524633A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007524633A5 JP2007524633A5 JP2006517702A JP2006517702A JP2007524633A5 JP 2007524633 A5 JP2007524633 A5 JP 2007524633A5 JP 2006517702 A JP2006517702 A JP 2006517702A JP 2006517702 A JP2006517702 A JP 2006517702A JP 2007524633 A5 JP2007524633 A5 JP 2007524633A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- independently hydrogen
- alkyl
- bcl
- gallate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 12
- 238000000034 method Methods 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- PBJKWGWHZVXBGU-UHFFFAOYSA-N 3-methyl-5-propan-2-yl-2-(1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)naphthalene-1,6,7-triol Chemical compound CC(C)C1=C(O)C(O)=CC2=C(O)C(C=3C(O)=C4C=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 PBJKWGWHZVXBGU-UHFFFAOYSA-N 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 6
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 6
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 claims 5
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 5
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 4
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims 4
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 230000003034 chemosensitisation Effects 0.000 claims 4
- 239000006114 chemosensitizer Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 claims 2
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 claims 2
- WMBWREPUVVBILR-NQIIRXRSSA-N (-)-gallocatechin gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-NQIIRXRSSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 239000012664 BCL-2-inhibitor Substances 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102000011727 Caspases Human genes 0.000 claims 2
- 108010076667 Caspases Proteins 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 claims 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 238000005481 NMR spectroscopy Methods 0.000 claims 2
- GPLOTACQBREROW-UHFFFAOYSA-N Phlegmanol A-acetat Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC1=2)C=C(O)C(=O)C1=C(O)C(O)=CC=2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GPLOTACQBREROW-UHFFFAOYSA-N 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- KMJPKUVSXFVQGZ-UHFFFAOYSA-N TF2B Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 KMJPKUVSXFVQGZ-UHFFFAOYSA-N 0.000 claims 2
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 claims 2
- BVMDSEFJGKQBKJ-UHFFFAOYSA-N Theaflavin 3'-gallate Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O BVMDSEFJGKQBKJ-UHFFFAOYSA-N 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000002875 fluorescence polarization Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- WDGFFVCWBZVLCE-UHFFFAOYSA-N purpurogallin Chemical class C1=CC=C(O)C(=O)C2=C1C=C(O)C(O)=C2O WDGFFVCWBZVLCE-UHFFFAOYSA-N 0.000 claims 2
- 235000014620 theaflavin Nutrition 0.000 claims 2
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 claims 2
- 229940026509 theaflavin Drugs 0.000 claims 2
- IKLDTEFDTLKDRK-UHFFFAOYSA-N theaflavin 3'-gallate Natural products OC1Cc2c(O)cc(O)cc2OC1c3cc4C=C(C=C(O)C(=O)c4c(O)c3O)C5Oc6cc(O)cc(O)c6CC5OC(=O)c7cc(O)c(O)c(O)c7 IKLDTEFDTLKDRK-UHFFFAOYSA-N 0.000 claims 2
- 235000002365 theaflavin-3'-gallate Nutrition 0.000 claims 2
- 229930013799 (-)-catechin Natural products 0.000 claims 1
- 235000007331 (-)-catechin Nutrition 0.000 claims 1
- PFTAWBLQPZVEMU-HIFRSBDPSA-N (-)-catechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-HIFRSBDPSA-N 0.000 claims 1
- LSHVYAFMTMFKBA-CTNGQTDRSA-N (-)-catechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-CTNGQTDRSA-N 0.000 claims 1
- CFNMUZCFSDMZPQ-GHXNOFRVSA-N 7-[(z)-3-methyl-4-(4-methyl-5-oxo-2h-furan-2-yl)but-2-enoxy]chromen-2-one Chemical compound C=1C=C2C=CC(=O)OC2=CC=1OC/C=C(/C)CC1OC(=O)C(C)=C1 CFNMUZCFSDMZPQ-GHXNOFRVSA-N 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229940009456 adriamycin Drugs 0.000 claims 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical group O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 claims 1
- 229950010817 alvocidib Drugs 0.000 claims 1
- 230000002424 anti-apoptotic effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- CXQWRCVTCMQVQX-UHFFFAOYSA-N cis-dihydroquercetin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-UHFFFAOYSA-N 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960000956 coumarin Drugs 0.000 claims 1
- 235000001671 coumarin Nutrition 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000006882 induction of apoptosis Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 238000000159 protein binding assay Methods 0.000 claims 1
- -1 t -Bu Chemical group 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48288603P | 2003-06-25 | 2003-06-25 | |
| PCT/US2004/020569 WO2005009434A2 (en) | 2003-06-25 | 2004-06-25 | Compounds and methods for inducing apoptosis in cancer cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011215077A Division JP2012025767A (ja) | 2003-06-25 | 2011-09-29 | 癌細胞におけるアポトーシスの誘導のための化合物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007524633A JP2007524633A (ja) | 2007-08-30 |
| JP2007524633A5 true JP2007524633A5 (https=) | 2008-12-18 |
Family
ID=34102647
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006517702A Pending JP2007524633A (ja) | 2003-06-25 | 2004-06-25 | 癌細胞におけるアポトーシスの誘導のための化合物および方法 |
| JP2011215077A Pending JP2012025767A (ja) | 2003-06-25 | 2011-09-29 | 癌細胞におけるアポトーシスの誘導のための化合物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011215077A Pending JP2012025767A (ja) | 2003-06-25 | 2011-09-29 | 癌細胞におけるアポトーシスの誘導のための化合物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US7812058B2 (https=) |
| EP (2) | EP1653943B3 (https=) |
| JP (2) | JP2007524633A (https=) |
| AT (2) | ATE478663T1 (https=) |
| AU (1) | AU2004258867B2 (https=) |
| CA (1) | CA2529507C (https=) |
| DE (2) | DE602004012279T3 (https=) |
| DK (1) | DK1653943T4 (https=) |
| ES (2) | ES2351581T3 (https=) |
| PL (1) | PL1653943T6 (https=) |
| PT (1) | PT1653943E (https=) |
| SI (1) | SI1653943T1 (https=) |
| WO (1) | WO2005009434A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432304B2 (en) | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
| WO2003038060A2 (en) * | 2001-11-01 | 2003-05-08 | The Regents Of The University Of Michigan | Small molecule inhibitors targeted at bcl-2 |
| JP2007524633A (ja) | 2003-06-25 | 2007-08-30 | ザ バーナム インスティチュート | 癌細胞におけるアポトーシスの誘導のための化合物および方法 |
| EP1732529A4 (en) * | 2004-03-25 | 2009-02-25 | Univ Michigan | GOSSYPOL KOKRISTALLE AND ITS USE |
| US20060144723A1 (en) * | 2004-11-02 | 2006-07-06 | Mary Fuller | Device for securing valuables |
| EP2197273B1 (en) * | 2007-10-01 | 2014-09-24 | Ascenta Therapeutics, Inc. | Process for preparing r-gossypol l-phenylalaninol dienamine |
| US8039668B2 (en) | 2008-10-17 | 2011-10-18 | Burnham Institute For Medical Research | Naphthalene-based inhibitors of anti-apoptotic proteins |
| EP2205088B1 (en) * | 2007-10-19 | 2018-02-21 | Burnham Institute for Medical Research | Naphthalene-based inhibitors of anti-apoptotic proteins |
| FR2924712B1 (fr) | 2007-12-06 | 2012-12-21 | Univ Maine | Derives du gossypol et de l'apogossypol, leurs preparations et leurs applications |
| GB0725077D0 (en) * | 2007-12-21 | 2008-01-30 | Univ Murcia | Antifolate com[ounds for the treatment of melanoma |
| WO2009126172A1 (en) * | 2008-04-11 | 2009-10-15 | The Trustees Of Columbia University In The City Of New York | Resistance to polyphenon e due to increased bcl-2 expression |
| CA2733930A1 (en) * | 2008-08-14 | 2010-02-18 | The Uab Research Foundation | Anti-arrhythmia agents, methods of their use, methods of their identification, and kits therefore |
| US8487131B2 (en) | 2009-04-15 | 2013-07-16 | Sanford-Burnham Medical Research Institute | Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2) |
| WO2011017096A2 (en) * | 2009-08-04 | 2011-02-10 | Mayo Foundation For Medical Education And Research | Methods of treating hematologic cancers |
| AU2010303324A1 (en) | 2009-10-08 | 2012-04-05 | Sanford-Burnham Medical Research Institute | Apogossypolone derivatives as anticancer agents |
| WO2014127191A1 (en) | 2013-02-15 | 2014-08-21 | The Regents Of The University Of Michigan | Compositions and methods relating to hindering dot1l recruitment by mll-fusion proteins |
| US9180226B1 (en) | 2014-08-07 | 2015-11-10 | Cook Medical Technologies Llc | Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof |
| US9655998B2 (en) | 2014-08-07 | 2017-05-23 | Cook Medical Technologies Llc | Encapsulated drug compositions and methods of use thereof |
| US11241520B2 (en) | 2014-08-07 | 2022-02-08 | Cook Medical Technologies Llc | Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| JP2018512450A (ja) * | 2015-03-19 | 2018-05-17 | ウェンディ アン エプスタインＥＰＳＴＥＩＮ， Ｗｅｎｄｙ Ａｎｎｅ | 女性の性的障害を治療するための化合物及び剤型 |
| RU2654711C1 (ru) * | 2017-07-10 | 2018-05-22 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Средство, обладающее апоптоз-индуцирующей активностью |
| CN115281419B (zh) * | 2018-04-20 | 2024-11-05 | 耐克创新有限合伙公司 | 带有板和中间流体填充囊的鞋底结构及其制造方法 |
| CN110128290B (zh) * | 2019-05-10 | 2022-04-29 | 江苏耐雀生物工程技术有限公司 | 红倍酚苯甲酰肼衍生物、中间体、制备方法及其应用 |
| CA3155694A1 (en) * | 2019-09-24 | 2021-04-01 | Genetec Inc. | Intermediary device for daisy chain and tree configuration in hybrid data/power connection |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5385936A (en) * | 1990-07-12 | 1995-01-31 | The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services | Gossypol acetic acid for the treatment of cancer |
| JPH1036260A (ja) * | 1996-07-18 | 1998-02-10 | Mitsui Norin Kk | 抗ガン剤の効力増強方法 |
| US5804567A (en) * | 1996-07-18 | 1998-09-08 | Cancer Institute (Hospital), Chinese Academy Of Medical Sciences | Method of increasing the effectiveness of anti-metabolites |
| US6428818B1 (en) | 1999-03-30 | 2002-08-06 | Purdue Research Foundation | Tea catechin formulations and processes for making same |
| US6608107B2 (en) * | 2000-12-15 | 2003-08-19 | Wackvom Limited | Methods and compositions to treat conditions associated with neovascularization |
| US7432304B2 (en) * | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
| WO2002097053A2 (en) * | 2001-05-30 | 2002-12-05 | The Regents Of The University Of Michigan | Small molecule antagonists of bcl2 family proteins |
| JP2007524633A (ja) * | 2003-06-25 | 2007-08-30 | ザ バーナム インスティチュート | 癌細胞におけるアポトーシスの誘導のための化合物および方法 |
-
2004
- 2004-06-25 JP JP2006517702A patent/JP2007524633A/ja active Pending
- 2004-06-25 DK DK04777151T patent/DK1653943T4/da active
- 2004-06-25 US US10/877,781 patent/US7812058B2/en not_active Expired - Fee Related
- 2004-06-25 AU AU2004258867A patent/AU2004258867B2/en not_active Ceased
- 2004-06-25 ES ES08003839T patent/ES2351581T3/es not_active Expired - Lifetime
- 2004-06-25 WO PCT/US2004/020569 patent/WO2005009434A2/en not_active Ceased
- 2004-06-25 PT PT04777151T patent/PT1653943E/pt unknown
- 2004-06-25 PL PL04777151T patent/PL1653943T6/pl unknown
- 2004-06-25 AT AT08003839T patent/ATE478663T1/de not_active IP Right Cessation
- 2004-06-25 DE DE602004012279T patent/DE602004012279T3/de not_active Expired - Lifetime
- 2004-06-25 SI SI200430628T patent/SI1653943T1/sl unknown
- 2004-06-25 EP EP04777151A patent/EP1653943B3/en not_active Expired - Lifetime
- 2004-06-25 AT AT04777151T patent/ATE387911T1/de not_active IP Right Cessation
- 2004-06-25 DE DE602004028880T patent/DE602004028880D1/de not_active Expired - Lifetime
- 2004-06-25 ES ES04777151T patent/ES2303096T7/es active Active
- 2004-06-25 EP EP08003839A patent/EP1938816B1/en not_active Expired - Lifetime
- 2004-06-25 CA CA2529507A patent/CA2529507C/en not_active Expired - Fee Related
-
2010
- 2010-10-07 US US12/900,319 patent/US8367644B2/en not_active Expired - Fee Related
-
2011
- 2011-09-29 JP JP2011215077A patent/JP2012025767A/ja active Pending
- 2011-12-19 US US13/329,611 patent/US20120269901A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007524633A5 (https=) | ||
| CA2529507A1 (en) | Compounds and methods for inducing apoptosis in cancer cells | |
| Mackenzie et al. | Curcumin induces cell‐arrest and apoptosis in association with the inhibition of constitutively active NF‐κB and STAT3 pathways in Hodgkin's lymphoma cells | |
| Wei et al. | BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins | |
| Leone et al. | Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins | |
| US9988405B2 (en) | O-phenyl chalcone compounds and uses thereof | |
| Luo et al. | Synthesis and anticancer activity evaluation of naphthalene-substituted triazole spirodienones | |
| Xie et al. | Capsaicin and dihydrocapsaicin induce apoptosis in human glioma cells via ROS and Ca2+‑mediated mitochondrial pathway | |
| Wei et al. | Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins | |
| Liu et al. | Effect of fraxetin on proliferation and apoptosis in breast cancer cells | |
| Li et al. | Pt (IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance | |
| Srivastava et al. | Synthesis and bio-evaluation of novel quinolino-stilbene derivatives as potential anticancer agents | |
| Wang et al. | Effect and mechanism of resveratrol on the apoptosis of lung adenocarcinoma cell line A549 | |
| Tan et al. | Pterostilbene inhibits lung squamous cell carcinoma growth in vitro and in vivo by inducing S phase arrest and apoptosis | |
| Kaplancıklı et al. | Synthesis and antiproliferative activity of new 1, 5-disubstituted tetrazoles bearing hydrazone moiety | |
| Xu et al. | Osthole induces lung cancer cell apoptosis through inhibition of inhibitor of apoptosis family proteins | |
| Rodrigues et al. | Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo | |
| Wang et al. | Targeting procaspase‐3 with WF‐208, a novel PAC‐1 derivative, causes selective cancer cell apoptosis | |
| Li et al. | Synthesis and biological evaluations of N′-substituted methylene-4-(quinoline-4-amino) benzoylhydrazides as potential anti-hepatoma agents | |
| Wei et al. | Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins | |
| Yang et al. | Redox cycling of a copper complex with benzaldehyde nitrogen mustard-2-pyridine carboxylic acid hydrazone contributes to its enhanced antitumor activity, but no change in the mechanism of action occurs after chelation | |
| AU2016212552B2 (en) | Compound containing indoleacetic acid core structure and use thereof | |
| Balachandran et al. | Synthetic investigation on chirally pure Mannich derivatives of pseudophenylpropanolamine and their anticancer properties against HepG-2 cells with inhibition of JAK2/STAT3 | |
| CN113200908B (zh) | 一种含叔胺的邻氨基苯甲酰胺类化合物及其制备与应用 | |
| EP3634403B1 (en) | Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma |